117 related articles for article (PubMed ID: 32976788)
41. The use of hydrogel spacer in men undergoing high-dose prostate cancer radiotherapy: results of a prospective phase 2 clinical trial.
Chao M; Lim Joon D; Khoo V; Lawrentschuk N; Ho H; Spencer S; Chan Y; Tan A; Pham T; Sengupta S; McMillan K; Liu M; Koufogiannis G; Cham CW; Foroudi F; Bolton D
World J Urol; 2019 Jun; 37(6):1111-1116. PubMed ID: 30251049
[TBL] [Abstract][Full Text] [Related]
42. Dosimetric uncertainty in prostate cancer proton radiotherapy.
Lin L; Vargas C; Hsi W; Indelicato D; Slopsema R; Li Z; Yeung D; Horne D; Palta J
Med Phys; 2008 Nov; 35(11):4800-7. PubMed ID: 19070212
[TBL] [Abstract][Full Text] [Related]
43. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer.
Leiker AJ; Desai NB; Folkert MR
Future Oncol; 2018 Nov; 14(26):2773-2788. PubMed ID: 29939069
[TBL] [Abstract][Full Text] [Related]
44. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
[TBL] [Abstract][Full Text] [Related]
45. How I Do It: Hydrogel spacer placement in men scheduled to undergo prostate radiotherapy.
Montoya J; Gross E; Karsh L
Can J Urol; 2018 Apr; 25(2):9288-9293. PubMed ID: 29680009
[TBL] [Abstract][Full Text] [Related]
46. Comparison of two different rectal spacers in prostate cancer external beam radiotherapy in terms of rectal sparing and volume consistency.
Wolf F; Gaisberger C; Ziegler I; Krenn E; Scherer P; Hruby S; Schätz T; Forstner R; Holzinger J; Vaszi A; Kametriser G; Steininger P; Deutschmann H; Sedlmayer F
Radiother Oncol; 2015 Aug; 116(2):221-5. PubMed ID: 26232129
[TBL] [Abstract][Full Text] [Related]
47. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
[TBL] [Abstract][Full Text] [Related]
48. A comparison between hydrogel spacer and endorectal balloon: An analysis of intrafraction prostate motion during proton therapy.
Hedrick SG; Fagundes M; Robison B; Blakey M; Renegar J; Artz M; Schreuder N
J Appl Clin Med Phys; 2017 Mar; 18(2):106-112. PubMed ID: 28300377
[TBL] [Abstract][Full Text] [Related]
49. Patient tolerance of rectal balloons in conformal radiation treatment of prostate cancer.
Ronson BB; Yonemoto LT; Rossi CJ; Slater JM; Slater JD
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1367-70. PubMed ID: 16488552
[TBL] [Abstract][Full Text] [Related]
50. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: a pooled prospective evaluation of bowel-associated quality of life.
Seymour ZA; Hamstra DA; Daignault-Newton S; Bosch W; Michalski J; Gay HA; Pinkawa M
BJU Int; 2020 Sep; 126(3):367-372. PubMed ID: 32333714
[TBL] [Abstract][Full Text] [Related]
51. Hydrogel spacer distribution within the perirectal space in patients undergoing radiotherapy for prostate cancer: Impact of spacer symmetry on rectal dose reduction and the clinical consequences of hydrogel infiltration into the rectal wall.
Fischer-Valuck BW; Chundury A; Gay H; Bosch W; Michalski J
Pract Radiat Oncol; 2017; 7(3):195-202. PubMed ID: 28089528
[TBL] [Abstract][Full Text] [Related]
52. First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy.
Beydoun N; Bucci JA; Chin YS; Malouf D; Enari E; Painter SD
Brachytherapy; 2013; 12(4):368-74. PubMed ID: 23453682
[TBL] [Abstract][Full Text] [Related]
53. Stereotactic body radiation therapy for prostate cancer-a review.
Haque W; Butler EB; Teh BS
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
[TBL] [Abstract][Full Text] [Related]
54. Proton therapy for prostate cancer: A review of the rationale, evidence, and current state.
Royce TJ; Efstathiou JA
Urol Oncol; 2019 Sep; 37(9):628-636. PubMed ID: 30527342
[TBL] [Abstract][Full Text] [Related]
55. Have we reached proton beam therapy dosimetric limitations? - A novel robust, delivery-efficient and continuous spot-scanning proton arc (SPArc) therapy is to improve the dosimetric outcome in treating prostate cancer.
Ding X; Li X; Qin A; Zhou J; Yan D; Stevens C; Krauss D; Kabolizdeh P
Acta Oncol; 2018 Mar; 57(3):435-437. PubMed ID: 28774218
[No Abstract] [Full Text] [Related]
56. Re: Proton vs intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.
Schild SE; Keole SR; Foote RL
J Natl Cancer Inst; 2013 May; 105(10):748. PubMed ID: 23559544
[No Abstract] [Full Text] [Related]
57. Maximizing rectal dose sparing with hydrogel: A retrospective planning study.
Paetkau O; Gagne IM; Pai HH; Lam J; Goulart J; Alexander A
J Appl Clin Med Phys; 2019 Apr; 20(4):91-98. PubMed ID: 30889318
[TBL] [Abstract][Full Text] [Related]
58. An overlap-volume-histogram based method for rectal dose prediction and automated treatment planning in the external beam prostate radiotherapy following hydrogel injection.
Yang Y; Ford EC; Wu B; Pinkawa M; van Triest B; Campbell P; Song DY; McNutt TR
Med Phys; 2013 Jan; 40(1):011709. PubMed ID: 23298079
[TBL] [Abstract][Full Text] [Related]
59. Comparing photon and proton-based hypofractioned SBRT for prostate cancer accounting for robustness and realistic treatment deliverability.
Goddard LC; Brodin NP; Bodner WR; Garg MK; Tomé WA
Br J Radiol; 2018 May; 91(1085):20180010. PubMed ID: 29436852
[TBL] [Abstract][Full Text] [Related]
60. Improved rectal dosimetry with the use of SpaceOAR during high-dose-rate brachytherapy.
Wu SY; Boreta L; Wu A; Cheung JP; Cunha JAM; Shinohara K; Chang AJ
Brachytherapy; 2018; 17(2):259-264. PubMed ID: 29203149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
